Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare ConferenceBusiness Wire • 03/06/23
Reata Pharmaceuticals wins key FDA approval for rare disease treatment Friedreich's ataxia, sending shares soaringProactive Investors • 03/01/23
Stocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts' over future operationsMarket Watch • 03/01/23
FDA approves Reata's rare nervous-system drug amid questions about changing regulatory environment for neuroscience treatmentsMarket Watch • 02/28/23
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich's AtaxiaBusiness Wire • 02/28/23
Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience UnitInvestors Business Daily • 02/27/23
Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 02/03/23
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare ConferenceBusiness Wire • 11/10/22